Skip to main content
NCBI home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1988 Jan;1(1):1–18. doi: 10.1128/cmr.1.1.1

Clostridium difficile: its disease and toxins.

D M Lyerly 1, H C Krivan 1, T D Wilkins 1
PMCID: PMC358025  PMID: 3144429

Abstract

Clostridium difficile is the etiologic agent of pseudomembranous colitis, a severe, sometimes fatal disease that occurs in adults undergoing antimicrobial therapy. The disease, ironically, has been most effectively treated with antibiotics, although some of the newer methods of treatment such as the replacement of the bowel flora may prove more beneficial for patients who continue to relapse with pseudomembranous colitis. The organism produces two potent exotoxins designated toxin A and toxin B. Toxin A is an enterotoxin believed to be responsible for the diarrhea and mucosal tissue damage which occur during the disease. Toxin B is an extremely potent cytotoxin, but its role in the disease has not been as well studied. There appears to be a cascade of events which result in the expression of the activity of these toxins, and these events, ranging from the recognition of a trisaccharide receptor by toxin A to the synergistic action of the toxins and their possible dissemination in the body, are discussed in this review. The advantages and disadvantages of the various assays, including tissue culture assay, enzyme immunoassay, and latex agglutination, currently used in the clinical diagnosis of the disease also are discussed.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams G. D., Allo M., Rifkin G. D., Fekety R., Silva J., Jr Mucosal damage mediated by clostridial toxin in experimental clindamycin-associated colitis. Gut. 1980 Jun;21(6):493–499. doi: 10.1136/gut.21.6.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Adler S. P., Chandrika T., Berman W. F. Clostridium difficile associated with pseudomembranous colitis. Occurrence in a 12-week-old infant without prior antibiotic therapy. Am J Dis Child. 1981 Sep;135(9):820–822. [PubMed] [Google Scholar]
  3. Ahlgren T., Florin I., Jarstrand C., Thelestam M. Loss of surface fibronectin from human lung fibroblasts exposed to cytotoxin from Clostridium difficile. Infect Immun. 1983 Mar;39(3):1470–1472. doi: 10.1128/iai.39.3.1470-1472.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Al-Jumaili I. J., Bint A. J. Simple method for isolation and presumptive identification of Clostridium difficile. Zentralbl Bakteriol Mikrobiol Hyg A. 1981;250(1-2):142–146. [PubMed] [Google Scholar]
  5. Al-Jumaili I. J., Shibley M., Lishman A. H., Record C. O. Incidence and origin of Clostridium difficile in neonates. J Clin Microbiol. 1984 Jan;19(1):77–78. doi: 10.1128/jcm.19.1.77-78.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Al-Mashat R. R., Taylor D. J. Bacteria in enteric lesions of cattle. Vet Rec. 1983 Jan 1;112(1):5–10. doi: 10.1136/vr.112.1.5. [DOI] [PubMed] [Google Scholar]
  7. Allo M., Silva J., Jr, Fekety R., Rifkin G. D., Waskin H. Prevention of clindamycin-induced colitis in hamsters by Clostridium sordellii antitoxin. Gastroenterology. 1979 Feb;76(2):351–355. [PubMed] [Google Scholar]
  8. Aronsson B., Granström M., Möllby R., Nord C. E. Enzyme immunoassay for detection of Clostridium difficile toxins A and B in patients with antibiotic-associated diarrhoea and colitis. Eur J Clin Microbiol. 1985 Apr;4(2):102–107. doi: 10.1007/BF02013572. [DOI] [PubMed] [Google Scholar]
  9. Banno Y., Kobayashi T., Kono H., Watanabe K., Ueno K., Nozawa Y. Biochemical characterization and biologic actions of two toxins (D-1 and D-2) from Clostridium difficile. Rev Infect Dis. 1984 Mar-Apr;6 (Suppl 1):S11–S20. doi: 10.1093/clinids/6.supplement_1.s11. [DOI] [PubMed] [Google Scholar]
  10. Bartlett J. G. Antibiotic-associated pseudomembranous colitis. Rev Infect Dis. 1979 May-Jun;1(3):530–539. doi: 10.1093/clinids/1.3.530. [DOI] [PubMed] [Google Scholar]
  11. Bartlett J. G., Chang T. W., Gurwith M., Gorbach S. L., Onderdonk A. B. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med. 1978 Mar 9;298(10):531–534. doi: 10.1056/NEJM197803092981003. [DOI] [PubMed] [Google Scholar]
  12. Bartlett J. G., Chang T. W., Moon N., Onderdonk A. B. Antibiotic-induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to support the pathogenic role of toxin-producing Clostridia. Am J Vet Res. 1978 Sep;39(9):1525–1530. [PubMed] [Google Scholar]
  13. Bartlett J. G., Chang T., Taylor N. S., Onderdonk A. B. Colitis induced by Clostridium difficile. Rev Infect Dis. 1979 Mar-Apr;1(2):370–378. doi: 10.1093/clinids/1.2.370. [DOI] [PubMed] [Google Scholar]
  14. Bartlett J. G., Moon N., Chang T. W., Taylor N., Onderdonk A. B. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978 Nov;75(5):778–782. [PubMed] [Google Scholar]
  15. Bartlett J. G., Onderdonk A. B., Cisneros R. L. Clindamycin-associated colitis in hamsters: protection with vancomycin. Gastroenterology. 1977 Oct;73(4 Pt 1):772–776. [PubMed] [Google Scholar]
  16. Bartlett J. G., Onderdonk A. B., Cisneros R. L., Kasper D. L. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis. 1977 Nov;136(5):701–705. doi: 10.1093/infdis/136.5.701. [DOI] [PubMed] [Google Scholar]
  17. Bartlett J. G., Taylor N. S., Chang T., Dzink J. Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr. 1980 Nov;33(11 Suppl):2521–2526. doi: 10.1093/ajcn/33.11.2521. [DOI] [PubMed] [Google Scholar]
  18. Bartlett J. G., Tedesco F. J., Shull S., Lowe B., Chang T. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology. 1980 Mar;78(3):431–434. [PubMed] [Google Scholar]
  19. Bartlett J. G. Treatment of Clostridium difficile colitis. Gastroenterology. 1985 Nov;89(5):1192–1195. doi: 10.1016/0016-5085(85)90227-6. [DOI] [PubMed] [Google Scholar]
  20. Bartlett J. G. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis. 1984 Mar-Apr;6 (Suppl 1):S235–S241. doi: 10.1093/clinids/6.supplement_1.s235. [DOI] [PubMed] [Google Scholar]
  21. Bartlett J. G., Willey S. H., Chang T. W., Lowe B. Cephalosporin-associated pseudomembranous colitis due to Clostridium difficile. JAMA. 1979 Dec 14;242(24):2683–2685. [PubMed] [Google Scholar]
  22. Bate G. Comparison of Minitek Anaerobe II, API An-Ident, and RapID ANA systems for identification of Clostridium difficile. Am J Clin Pathol. 1986 Jun;85(6):716–718. doi: 10.1093/ajcp/85.6.716. [DOI] [PubMed] [Google Scholar]
  23. Boenning D. A., Fleisher G. R., Campos J. M., Hulkower C. W., Quinlan R. W. Clostridium difficile in a pediatric outpatient population. Pediatr Infect Dis. 1982 Sep-Oct;1(5):336–338. doi: 10.1097/00006454-198209000-00011. [DOI] [PubMed] [Google Scholar]
  24. Bolton R. P., Culshaw M. A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut. 1986 Oct;27(10):1169–1172. doi: 10.1136/gut.27.10.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Bolton R. P., Sherriff R. J., Read A. E. Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet. 1980 Feb 23;1(8165):383–384. doi: 10.1016/s0140-6736(80)90940-x. [DOI] [PubMed] [Google Scholar]
  26. Bolton R. P., Tait S. K., Dear P. R., Losowsky M. S. Asymptomatic neonatal colonisation by Clostridium difficile. Arch Dis Child. 1984 May;59(5):466–472. doi: 10.1136/adc.59.5.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Borriello S. P., Barclay F. E. An in-vitro model of colonisation resistance to Clostridium difficile infection. J Med Microbiol. 1986 Jun;21(4):299–309. doi: 10.1099/00222615-21-4-299. [DOI] [PubMed] [Google Scholar]
  28. Borriello S. P., Barclay F. E., Reed P. J., Welch A. R., Brown J. D., Burdon D. W. Analysis of latex agglutination test for Clostridium difficile toxin A (D-1) and differentiation between C difficile toxins A and B and latex reactive protein. J Clin Pathol. 1987 May;40(5):573–580. doi: 10.1136/jcp.40.5.573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Bowden T. A., Jr, Mansberger A. R., Jr, Lykins L. E. Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. Am Surg. 1981 Apr;47(4):178–183. [PubMed] [Google Scholar]
  30. Brettle R. P., Wallace E. Clostridium difficile-associated diarrhoea. J Infect. 1984 Mar;8(2):123–128. doi: 10.1016/s0163-4453(84)92443-5. [DOI] [PubMed] [Google Scholar]
  31. Brook I. Isolation of toxin producing Clostridium difficile from two children with oxacillin- and dicloxacillin-associated diarrhea. Pediatrics. 1980 Jun;65(6):1154–1156. [PubMed] [Google Scholar]
  32. Browne R. A., Fekety R., Jr, Silva J., Jr, Boyd D. I., Work C. O., Abrams G. D. The protective effect of vancomycin on clindamycin-induced colitis in hamsters. Johns Hopkins Med J. 1977 Oct;141(4):183–192. [PubMed] [Google Scholar]
  33. Buggy B. P., Wilson K. H., Fekety R. Comparison of methods for recovery of Clostridium difficile from an environmental surface. J Clin Microbiol. 1983 Aug;18(2):348–352. doi: 10.1128/jcm.18.2.348-352.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Burdon D. W., Brown J. D., Youngs D. J., Arabi Y., Shinagawa N., Alexander-Williams J., Keighley M. R., George R. H. Antibiotic susceptibility of Clostridium difficile. J Antimicrob Chemother. 1979 May;5(3):307–310. doi: 10.1093/jac/5.3.307. [DOI] [PubMed] [Google Scholar]
  35. Cashore W. J., Peter G., Lauermann M., Stonestreet B. S., Oh W. Clostridia colonization and clostridial toxin in neonatal necrotizing enterocolitis. J Pediatr. 1981 Feb;98(2):308–311. doi: 10.1016/s0022-3476(81)80667-1. [DOI] [PubMed] [Google Scholar]
  36. Chang T. W., Bartlett J. G., Gorbach S. L., Onderdonk A. B. Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun. 1978 May;20(2):526–529. doi: 10.1128/iai.20.2.526-529.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Chang T. W., Gorbach S. L., Bartlett J. G. Inhibition of binding of Clostridium difficile toxin by steroids. J Infect Dis. 1980 Jul;142(1):113–113. doi: 10.1093/infdis/142.1.113. [DOI] [PubMed] [Google Scholar]
  38. Chang T. W., Sullivan N. M., Wilkins T. D. Insusceptibility of fetal intestinal mucosa and fetal cells to Clostridium difficile toxins. Zhongguo Yao Li Xue Bao. 1986 Sep;7(5):448–453. [PubMed] [Google Scholar]
  39. Colardyn F., Verschraegen G., Claeys G., Vogelaers D. Clostridium difficile-associated diarrhoea during treatment with imipenem. Eur J Clin Microbiol. 1984 Dec;3(6):565–566. doi: 10.1007/BF02013624. [DOI] [PubMed] [Google Scholar]
  40. Collignon A., Cotte-Laffitte J., Quero A. M., Torlotin J. C. Clostridium difficile et sa cytotoxine dans les selles de jeunes enfants hospitalisés. Influence du traitement antibiotique. Pathol Biol (Paris) 1986 Nov;34(9):977–982. [PubMed] [Google Scholar]
  41. Corthier G., Dubos F., Raibaud P. Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria. Appl Environ Microbiol. 1985 Jan;49(1):250–252. doi: 10.1128/aem.49.1.250-252.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Cudmore M. A., Silva J., Jr, Fekety R., Liepman M. K., Kim K. H. Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med. 1982 Feb;142(2):333–335. [PubMed] [Google Scholar]
  43. Czuprynski C. J., Johnson W. J., Balish E., Wilkins T. Pseudomembranous colitis in Clostridium difficile-monoassociated rats. Infect Immun. 1983 Mar;39(3):1368–1376. doi: 10.1128/iai.39.3.1368-1376.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. D'Ari L., Barker H. A. p-Cresol formation by cell-free extracts of Clostridium difficile. Arch Microbiol. 1985 Dec;143(3):311–312. doi: 10.1007/BF00411256. [DOI] [PubMed] [Google Scholar]
  45. Decaux G. M., Devroede C. Acute colitis related to spiramycin. Lancet. 1978 Nov 4;2(8097):993–993. doi: 10.1016/s0140-6736(78)92555-2. [DOI] [PubMed] [Google Scholar]
  46. Deery H. G., Jones P. G., Kauffman C. A., Fekety R., Silva J., Sell T. L., Supena R. B. Effect of therapy with latamoxef (moxalactam) on carriage of Clostridium difficile. J Antimicrob Chemother. 1984 May;13(5):521–524. doi: 10.1093/jac/13.5.521. [DOI] [PubMed] [Google Scholar]
  47. Delmee M., Bulliard G., Simon G. Application of a technique for serogrouping Clostridium difficile in an outbreak of antibiotic-associated diarrhoea. J Infect. 1986 Jul;13(1):5–9. doi: 10.1016/s0163-4453(86)92095-5. [DOI] [PubMed] [Google Scholar]
  48. Donta S. T., Myers M. G. Clostridium difficile toxin in asymptomatic neonates. J Pediatr. 1982 Mar;100(3):431–434. doi: 10.1016/s0022-3476(82)80454-x. [DOI] [PubMed] [Google Scholar]
  49. Dorman S. A., Liggoria E., Winn W. C., Jr, Beeken W. L. Isolation of Clostridium difficile from patients with inactive Crohn's disease. Gastroenterology. 1982 Jun;82(6):1348–1351. [PubMed] [Google Scholar]
  50. Dudley M. N., McLaughlin J. C., Carrington G., Frick J., Nightingale C. H., Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med. 1986 Jun;146(6):1101–1104. [PubMed] [Google Scholar]
  51. Dzink J., Bartlett J. G. In vitro susceptibility of Clostridium difficile isolates from patients with antibiotic-associated diarrhea or colitis. Antimicrob Agents Chemother. 1980 Apr;17(4):695–698. doi: 10.1128/aac.17.4.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Ehrich M., Van Tassell R. L., Libby J. M., Wilkins T. D. Production of Clostridium difficile antitoxin. Infect Immun. 1980 Jun;28(3):1041–1043. doi: 10.1128/iai.28.3.1041-1043.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Ellis M. E., Watson B. M., Milewski P. J., Jones G. Clostridium difficile colitis unassociated with antibiotic therapy. Br J Surg. 1983 Apr;70(4):242–243. doi: 10.1002/bjs.1800700420. [DOI] [PubMed] [Google Scholar]
  54. Elmer G. W., McFarland L. V. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother. 1987 Jan;31(1):129–131. doi: 10.1128/aac.31.1.129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Eto T., Ichikawa Y., Nishimura K., Ando S., Yamakawa T. Chemistry of lipid of the posthemyolytic residue or stroma of erythrocytes. XVI. Occurrence of ceramide pentasaccharide in the membrane of erythrocytes and reticulocytes of rabbit. J Biochem. 1968 Aug;64(2):205–213. doi: 10.1093/oxfordjournals.jbchem.a128881. [DOI] [PubMed] [Google Scholar]
  56. Fekety R., Silva J., Armstrong J., Allo M., Browne R., Ebright J., Lusk R., Rifkin G., Toshniwal R. Treatment of antibiotic-associated enterocolitis with vancomycin. Rev Infect Dis. 1981 Nov-Dec;3 Suppl:S273–S281. [PubMed] [Google Scholar]
  57. Fekety R., Silva J., Toshniwal R., Allo M., Armstrong J., Browne R., Ebright J., Rifkin G. Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters. Rev Infect Dis. 1979 Mar-Apr;1(2):386–397. doi: 10.1093/clinids/1.2.386. [DOI] [PubMed] [Google Scholar]
  58. Fernie D. S., Thomson R. O., Batty I., Walker P. D. Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev Biol Stand. 1983;53:325–332. [PubMed] [Google Scholar]
  59. Finegold S. M. Clinical considerations in the diagnosis of antimicrobial agent-associated gastroenteritis. Diagn Microbiol Infect Dis. 1986 Mar;4(3 Suppl):87S–91S. doi: 10.1016/s0732-8893(86)80046-3. [DOI] [PubMed] [Google Scholar]
  60. Florin I., Thelestam M. ADP-ribosylation in cultured cells treated with Clostridium difficile toxin B. Biochem Biophys Res Commun. 1986 Aug 29;139(1):64–70. doi: 10.1016/s0006-291x(86)80080-8. [DOI] [PubMed] [Google Scholar]
  61. Florin I., Thelestam M. Intoxication of cultured human lung fibroblasts with Clostridium difficile toxin. Infect Immun. 1981 Jul;33(1):67–74. doi: 10.1128/iai.33.1.67-74.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Florin I., Thelestam M. Lysosomal involvement in cellular intoxication with Clostridium difficile toxin B. Microb Pathog. 1986 Aug;1(4):373–385. doi: 10.1016/0882-4010(86)90069-0. [DOI] [PubMed] [Google Scholar]
  63. Florin I., Thelestam M. Polyphosphate-mediated protection from cellular intoxication with Clostridium difficile toxin B. Biochim Biophys Acta. 1984 Oct 12;805(2):131–136. doi: 10.1016/0167-4889(84)90159-9. [DOI] [PubMed] [Google Scholar]
  64. Fournier G., Orgiazzi J., Lenoir B., Dechavanne M. Pseudomembranous colitis probably due to rifampicin. Lancet. 1980 Jan 12;1(8159):101–101. doi: 10.1016/s0140-6736(80)90531-0. [DOI] [PubMed] [Google Scholar]
  65. Frieben W. R., Duncan C. L. Homology between enterotoxin protein and spore structural protein in Clostridium perfringens type A. Eur J Biochem. 1973 Nov 15;39(2):393–401. doi: 10.1111/j.1432-1033.1973.tb03137.x. [DOI] [PubMed] [Google Scholar]
  66. George R. H., Symonds J. M., Dimock F., Brown J. D., Arabi Y., Shinagawa N., Keighley M. R., Alexander-Williams J., Burdon D. W. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J. 1978 Mar 18;1(6114):695–695. doi: 10.1136/bmj.1.6114.695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. George W. L. Antimicrobial agent-associated colitis and diarrhea. West J Med. 1980 Aug;133(2):115–123. [PMC free article] [PubMed] [Google Scholar]
  68. George W. L. Antimicrobial agent-associated colitis and diarrhea: historical background and clinical aspects. Rev Infect Dis. 1984 Mar-Apr;6 (Suppl 1):S208–S213. doi: 10.1093/clinids/6.supplement_1.s208. [DOI] [PubMed] [Google Scholar]
  69. George W. L., Sutter V. L., Citron D., Finegold S. M. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol. 1979 Feb;9(2):214–219. doi: 10.1128/jcm.9.2.214-219.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. George W. L., Sutter V. L., Goldstein E. J., Ludwig S. L., Finegold S. M. Aetiology of antimicrobial-agent-associated colitis. Lancet. 1978 Apr 15;1(8068):802–803. doi: 10.1016/s0140-6736(78)93001-5. [DOI] [PubMed] [Google Scholar]
  71. Gianfrilli P., Pantosti A., Luzzi I. Evaluation of gas-liquid chromatography for the rapid diagnosis of Clostridium difficile associated disease. J Clin Pathol. 1985 Jun;38(6):690–693. doi: 10.1136/jcp.38.6.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Gilligan P. H., McCarthy L. R., Genta V. M. Relative frequency of Clostridium difficile in patients with diarrheal disease. J Clin Microbiol. 1981 Jul;14(1):26–31. doi: 10.1128/jcm.14.1.26-31.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Goulston S. J., McGovern V. J. Pseudo-membranous colitis. Gut. 1965 Jun;6(3):207–212. doi: 10.1136/gut.6.3.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Greenfield C., Aguilar Ramirez J. R., Pounder R. E., Williams T., Danvers M., Marper S. R., Noone P. Clostridium difficile and inflammatory bowel disease. Gut. 1983 Aug;24(8):713–717. doi: 10.1136/gut.24.8.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Gurwith M. J., Langston C., Citron D. M. Toxin-producing bacteria in infants. Lack of an association with sudden infant death syndrome. Am J Dis Child. 1981 Dec;135(12):1104–1106. doi: 10.1001/archpedi.1981.02130360012006. [DOI] [PubMed] [Google Scholar]
  76. Gurwith M. J., Rabin H. R., Love K. Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study. J Infect Dis. 1977 Mar;135 (Suppl):S104–S110. doi: 10.1093/infdis/135.supplement.s104. [DOI] [PubMed] [Google Scholar]
  77. Hafiz S., McEntegart M. G., Morton R. S., Waitkins S. A. Clostridium defficiel in the urogenital tract of males and females. Lancet. 1975 Feb 22;1(7904):420–421. doi: 10.1016/s0140-6736(75)91489-0. [DOI] [PubMed] [Google Scholar]
  78. Han V. K., Sayed H., Chance G. W., Brabyn D. G., Shaheed W. A. An outbreak of Clostridium difficile necrotizing enterocolitis: a case for oral vancomycin therapy? Pediatrics. 1983 Jun;71(6):935–941. [PubMed] [Google Scholar]
  79. Hanfland P., Egge H., Dabrowski U., Kuhn S., Roelcke D., Dabrowski J. Isolation and characterization of an I-active ceramide decasaccharide from rabbit erythrocyte membranes. Biochemistry. 1981 Sep 1;20(18):5310–5319. doi: 10.1021/bi00521a034. [DOI] [PubMed] [Google Scholar]
  80. Haslam S. C., Ketley J. M., Mitchell T. J., Stephen J., Burdon D. W., Candy D. C. Growth of Clostridium difficile and production of toxins A and B in complex and defined media. J Med Microbiol. 1986 Jun;21(4):293–297. doi: 10.1099/00222615-21-4-293. [DOI] [PubMed] [Google Scholar]
  81. Holst E., Helin I., Mårdh P. A. Recovery of Clostridium difficile from children. Scand J Infect Dis. 1981;13(1):41–45. doi: 10.1080/00365548.1981.11690365. [DOI] [PubMed] [Google Scholar]
  82. Humphrey C. D., Lushbaugh W. B., Condon C. W., Pittman J. C., Pittman F. E. Light and electron microscopic studies of antibiotic associated colitis in the hamster. Gut. 1979 Jan;20(1):6–15. doi: 10.1136/gut.20.1.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Hächler H., Wüst J. Reexamination by bacteriophage typing of Clostridium difficile strains isolated during a nosocomial outbreak. J Clin Microbiol. 1984 Sep;20(3):604–604. doi: 10.1128/jcm.20.3.604-.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Jarvis W., Nunez-Monteil O., Thompson F., Dowell V., Towns M., Morris G., Vogler W., Winton E., Hill E. False-positive counterimmunoelectrophoresis tests for Clostridium difficile: the role of Clostridium bifermentans and Clostridium sordellii. J Infect Dis. 1983 Dec;148(6):1168–1169. doi: 10.1093/infdis/148.6.1168a. [DOI] [PubMed] [Google Scholar]
  85. Jarvis W., Nunez-Montiel O., Thompson F., Dowell V., Towns M., Morris G., Hill E. Comparison of bacterial isolation, cytotoxicity assay, and counterimmunoelectrophoresis for the detection of Clostridium difficile and its toxin. J Infect Dis. 1983 Apr;147(4):778–778. doi: 10.1093/infdis/147.4.778. [DOI] [PubMed] [Google Scholar]
  86. Jones R. L., Adney W. S., Shideler R. K. Isolation of Clostridium difficile and detection of cytotoxin in the feces of diarrheic foals in the absence of antimicrobial treatment. J Clin Microbiol. 1987 Jul;25(7):1225–1227. doi: 10.1128/jcm.25.7.1225-1227.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Justus P. G., Martin J. L., Goldberg D. A., Taylor N. S., Bartlett J. G., Alexander R. W., Mathias J. R. Myoelectric effects of Clostridium difficile: motility-altering factors distinct from its cytotoxin and enterotoxin in rabbits. Gastroenterology. 1982 Oct;83(4):836–843. [PubMed] [Google Scholar]
  88. Kabins S. A., Spira T. J. Outbreak of clindamycin-associated colitis. Ann Intern Med. 1975 Dec;83(6):830–831. doi: 10.7326/0003-4819-83-6-830. [DOI] [PubMed] [Google Scholar]
  89. Kamiya S., Nakamura S., Yamakawa K., Nishida S. Evaluation of a commercially available latex immunoagglutination test kit for detection of Clostridium difficile D-1 toxin. Microbiol Immunol. 1986;30(2):177–181. doi: 10.1111/j.1348-0421.1986.tb00932.x. [DOI] [PubMed] [Google Scholar]
  90. Keighley M. R., Youngs D., Johnson M., Allan R. N., Burdon D. W. Clostridium difficile toxin in acute diarrhoea complicating inflammatory bowel disease. Gut. 1982 May;23(5):410–414. doi: 10.1136/gut.23.5.410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Kelly M. T., Champagne S. G., Sherlock C. H., Noble M. A., Freeman H. J., Smith J. A. Commercial latex agglutination test for detection of Clostridium difficile-associated diarrhea. J Clin Microbiol. 1987 Jul;25(7):1244–1247. doi: 10.1128/jcm.25.7.1244-1247.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Ketley J. M., Haslam S. C., Mitchell T. J., Stephen J., Candy D. C., Burdon D. W. Production and release of toxins A and B by Clostridium difficile. J Med Microbiol. 1984 Dec;18(3):385–391. doi: 10.1099/00222615-18-3-385. [DOI] [PubMed] [Google Scholar]
  93. Ketley J. M., Mitchell T. J., Haslam S. C., Stephen J., Candy D. C., Burdon D. W. Sporogenesis and toxin A production by Clostridium difficile. J Med Microbiol. 1986 Aug;22(1):33–38. doi: 10.1099/00222615-22-1-33. [DOI] [PubMed] [Google Scholar]
  94. Khan M. Y., Hall W. H. Staphylococcal enterocolitis--treatment with oral vancomycin. Ann Intern Med. 1966 Jul;65(1):1–8. doi: 10.7326/0003-4819-65-1-1. [DOI] [PubMed] [Google Scholar]
  95. Kim K. H., Fekety R., Batts D. H., Brown D., Cudmore M., Silva J., Jr, Waters D. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981 Jan;143(1):42–50. doi: 10.1093/infdis/143.1.42. [DOI] [PubMed] [Google Scholar]
  96. Kim K., DuPont H. L., Pickering L. K. Outbreaks of diarrhea associated with Clostridium difficile and its toxin in day-care centers: evidence of person-to-person spread. J Pediatr. 1983 Mar;102(3):376–382. doi: 10.1016/s0022-3476(83)80652-0. [DOI] [PubMed] [Google Scholar]
  97. Kim K., Pickering L. K., DuPont H. L., Sullivan N., Wilkins T. In vitro and in vivo neutralizing activity of human colostrum and milk against purified toxins A and B of Clostridium difficile. J Infect Dis. 1984 Jul;150(1):57–62. doi: 10.1093/infdis/150.1.57. [DOI] [PubMed] [Google Scholar]
  98. Knoop F. C. Clindamycin-associated enterocolitis in guinea pigs: evidence for a bacterial toxin. Infect Immun. 1979 Jan;23(1):31–33. doi: 10.1128/iai.23.1.31-33.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Kreutzer E. W., Milligan F. D. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J. 1978 Sep;143(3):67–72. [PubMed] [Google Scholar]
  100. Krishnan C. Detection of Clostridium difficile toxins by enzyme immunoassay. J Hyg (Lond) 1986 Feb;96(1):5–12. doi: 10.1017/s0022172400062471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Krivan H. C., Clark G. F., Smith D. F., Wilkins T. D. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun. 1986 Sep;53(3):573–581. doi: 10.1128/iai.53.3.573-581.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Krivan H. C., Wilkins T. D. Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun. 1987 Aug;55(8):1873–1877. doi: 10.1128/iai.55.8.1873-1877.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Kudhair A., Delmée M., Wauters G. Rapid identification of Clostridium difficile by determination of leucine arylamidase activity. Eur J Clin Microbiol. 1986 Apr;5(2):160–161. doi: 10.1007/BF02013973. [DOI] [PubMed] [Google Scholar]
  104. Kuijper E. J., Oudbier J. H., Stuifbergen W. N., Jansz A., Zanen H. C. Application of whole-cell DNA restriction endonuclease profiles to the epidemiology of Clostridium difficile-induced diarrhea. J Clin Microbiol. 1987 Apr;25(4):751–753. doi: 10.1128/jcm.25.4.751-753.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. LaMont J. T., Trnka Y. M. Therapeutic implications of Clostridium difficile toxin during relapse of chronic inflammatory bowel disease. Lancet. 1980 Feb 23;1(8165):381–383. doi: 10.1016/s0140-6736(80)90939-3. [DOI] [PubMed] [Google Scholar]
  106. Larson H. E., Barclay F. E., Honour P., Hill I. D. Epidemiology of Clostridium difficile in infants. J Infect Dis. 1982 Dec;146(6):727–733. doi: 10.1093/infdis/146.6.727. [DOI] [PubMed] [Google Scholar]
  107. Larson H. E., Parry J. V., Price A. B., Davies D. R., Dolby J., Tyrrell D. A. Undescribed toxin in pseudomembranous colitis. Br Med J. 1977 May 14;1(6071):1246–1248. doi: 10.1136/bmj.1.6071.1246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Larson H. E., Price A. B., Honour P., Borriello S. P. Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet. 1978 May 20;1(8073):1063–1066. doi: 10.1016/s0140-6736(78)90912-1. [DOI] [PubMed] [Google Scholar]
  109. Larson H. E., Price A. B. Pseudomembranous colitis: Presence of clostridial toxin. Lancet. 1977 Dec 24;2(8052-8053):1312–1314. doi: 10.1016/s0140-6736(77)90363-4. [DOI] [PubMed] [Google Scholar]
  110. Laughon B. E., Viscidi R. P., Gdovin S. L., Yolken R. H., Bartlett J. G. Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis. 1984 May;149(5):781–788. doi: 10.1093/infdis/149.5.781. [DOI] [PubMed] [Google Scholar]
  111. Levett P. N. Clostridium difficile in habitats other than the human gastro-intestinal tract. J Infect. 1986 May;12(3):253–263. doi: 10.1016/s0163-4453(86)94294-5. [DOI] [PubMed] [Google Scholar]
  112. Levett P. N. Detection of Clostridium difficile in faeces by direct gas liquid chromatography. J Clin Pathol. 1984 Feb;37(2):117–119. doi: 10.1136/jcp.37.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Levett P. N. Effect of antibiotic concentration in a selective medium on the isolation of Clostridium difficile from faecal specimens. J Clin Pathol. 1985 Feb;38(2):233–234. doi: 10.1136/jcp.38.2.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Levett P. N. Identification of Clostridium difficile using the API ZYM system. Eur J Clin Microbiol. 1985 Oct;4(5):505–507. doi: 10.1007/BF02014434. [DOI] [PubMed] [Google Scholar]
  115. Levett P. N., Phillips K. D. Gas chromatographic identification of Clostridium difficile and detection of cytotoxin from a modified selective medium. J Clin Pathol. 1985 Jan;38(1):82–85. doi: 10.1136/jcp.38.1.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Libby J. M., Donta S. T., Wilkins T. D. Clostridium difficile toxin A in infants. J Infect Dis. 1983 Sep;148(3):606–606. doi: 10.1093/infdis/148.3.606. [DOI] [PubMed] [Google Scholar]
  117. Libby J. M., Jortner B. S., Wilkins T. D. Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun. 1982 May;36(2):822–829. doi: 10.1128/iai.36.2.822-829.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Libby J. M., Wilkins T. D. Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun. 1982 Jan;35(1):374–376. doi: 10.1128/iai.35.1.374-376.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Lusk R. H., Fekety R., Silva J., Browne R. A., Ringler D. H., Abrams G. D. Clindamycin-induced enterocolitis in hamsters. J Infect Dis. 1978 Apr;137(4):464–475. doi: 10.1093/infdis/137.4.464. [DOI] [PubMed] [Google Scholar]
  120. Lyerly D. M., Lockwood D. E., Richardson S. H., Wilkins T. D. Biological activities of toxins A and B of Clostridium difficile. Infect Immun. 1982 Mar;35(3):1147–1150. doi: 10.1128/iai.35.3.1147-1150.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Lyerly D. M., Phelps C. J., Toth J., Wilkins T. D. Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun. 1986 Oct;54(1):70–76. doi: 10.1128/iai.54.1.70-76.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Lyerly D. M., Phelps C. J., Wilkins T. D. Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol. 1985 Jan;21(1):12–14. doi: 10.1128/jcm.21.1.12-14.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Lyerly D. M., Saum K. E., MacDonald D. K., Wilkins T. D. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun. 1985 Feb;47(2):349–352. doi: 10.1128/iai.47.2.349-352.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Lyerly D. M., Sullivan N. M., Wilkins T. D. Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol. 1983 Jan;17(1):72–78. doi: 10.1128/jcm.17.1.72-78.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Lyerly D. M., Wilkins T. D. Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol. 1986 Mar;23(3):622–623. doi: 10.1128/jcm.23.3.622-623.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Lönnroth I., Lange S. Toxin A of Clostridium difficile: production, purification and effect in mouse intestine. Acta Pathol Microbiol Immunol Scand B. 1983 Dec;91(6):395–400. doi: 10.1111/j.1699-0463.1983.tb00066.x. [DOI] [PubMed] [Google Scholar]
  127. Lüderitz O., Simmons D. A., Westphal G. The immunochemistry of Salmonella chemotype VI O-antigens. The structure of oligosaccharides from Salmonella group U (o 43) lipopolysaccharides. Biochem J. 1965 Dec;97(3):820–826. doi: 10.1042/bj0970820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Mahony D. E., Bell P. D., Easterbrook K. B. Two bacteriophages of Clostridium difficile. J Clin Microbiol. 1985 Feb;21(2):251–254. doi: 10.1128/jcm.21.2.251-254.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Makin T. Rapid identification of Clostridium difficile by direct detection of volatile organic acids from primary isolation media. J Clin Pathol. 1984 Jun;37(6):711–712. doi: 10.1136/jcp.37.6.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Malamou-Ladas H., O'Farrell S., Nash J. Q., Tabaqchali S. Isolation of Clostridium difficile from patients and the environment of hospital wards. J Clin Pathol. 1983 Jan;36(1):88–92. doi: 10.1136/jcp.36.1.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Marler L., Allen S., Siders J. Rapid enzymatic characterization of clinically encountered anaerobic bacteria with the API ZYM system. Eur J Clin Microbiol. 1984 Aug;3(4):294–300. doi: 10.1007/BF01977476. [DOI] [PubMed] [Google Scholar]
  132. Massot J., Sanchez O., Couchy R., Astoin J., Parodi A. L. Bacterio-pharmacological activity of Saccharomyces boulardii in clindamycin-induced colitis in the hamster. Arzneimittelforschung. 1984;34(7):794–797. [PubMed] [Google Scholar]
  133. Meyers S., Mayer L., Bottone E., Desmond E., Janowitz H. D. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology. 1981 Apr;80(4):697–670. [PubMed] [Google Scholar]
  134. Mitchell T. J., Ketley J. M., Haslam S. C., Stephen J., Burdon D. W., Candy D. C., Daniel R. Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut. 1986 Jan;27(1):78–85. doi: 10.1136/gut.27.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Moskovitz M., Bartlett J. G. Recurrent pseudomembranous colitis unassociated with prior antibiotic therapy. Arch Intern Med. 1981 Apr;141(5):663–664. [PubMed] [Google Scholar]
  136. Muldrow L. L., Archibold E. R., Nunez-Montiel O. L., Sheehy R. J. Survey of the extrachromosomal gene pool of Clostridium difficile. J Clin Microbiol. 1982 Oct;16(4):637–640. doi: 10.1128/jcm.16.4.637-640.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Mulligan M. E. Epidemiology of Clostridium difficile-induced intestinal disease. Rev Infect Dis. 1984 Mar-Apr;6 (Suppl 1):S222–S228. doi: 10.1093/clinids/6.supplement_1.s222. [DOI] [PubMed] [Google Scholar]
  138. Mulligan M. E., Halebian S., Kwok R. Y., Cheng W. C., Finegold S. M., Anselmo C. R., Gerding D. N., Peterson L. R. Bacterial agglutination and polyacrylamide gel electrophoresis for typing Clostridium difficile. J Infect Dis. 1986 Feb;153(2):267–271. doi: 10.1093/infdis/153.2.267. [DOI] [PubMed] [Google Scholar]
  139. Mårdh P. A., Helin I., Colleen I., Oberg M., Holst E. Clostridium difficile toxin in faecal specimens of healthy children and children with diarrhoea. Acta Paediatr Scand. 1982 Mar;71(2):275–278. doi: 10.1111/j.1651-2227.1982.tb09414.x. [DOI] [PubMed] [Google Scholar]
  140. Nachamkin I., Lotz-Nolan L., Skalina D. Evaluation of a commercial cytotoxicity assay for detection of Clostridium difficile toxin. J Clin Microbiol. 1986 May;23(5):954–955. doi: 10.1128/jcm.23.5.954-955.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Nachamkin I., Lotz-Nolan L., Skalina D. Evaluation of a commercial cytotoxicity assay for detection of Clostridium difficile toxin. J Clin Microbiol. 1986 May;23(5):954–955. doi: 10.1128/jcm.23.5.954-955.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Nakamura S., Mikawa M., Tanabe N., Yamakawa K., Nishida S. Effect of clindamycin on cytotoxin production by Clostridium difficile. Microbiol Immunol. 1982;26(11):985–992. doi: 10.1111/j.1348-0421.1982.tb00248.x. [DOI] [PubMed] [Google Scholar]
  143. Nakamura S., Tanabe N., Yamakawa K., Nishida S. Cytotoxin production by Clostridium sordellii strains. Microbiol Immunol. 1983;27(6):495–502. doi: 10.1111/j.1348-0421.1983.tb00611.x. [DOI] [PubMed] [Google Scholar]
  144. O'Farrell S., Wilks M., Nash J. Q., Tabaqchali S. A selective enrichment broth for the isolation of Clostridium difficile. J Clin Pathol. 1984 Jan;37(1):98–99. doi: 10.1136/jcp.37.1.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Onderdonk A. B., Cisneros R. L., Bartlett J. G. Clostridium difficile in gnotobiotic mice. Infect Immun. 1980 Apr;28(1):277–282. doi: 10.1128/iai.28.1.277-282.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Onderdonk A. B., Lowe B. R., Bartlett J. G. Effect of environmental stress on Clostridium difficile toxin levels during continuous cultivation. Appl Environ Microbiol. 1979 Oct;38(4):637–641. doi: 10.1128/aem.38.4.637-641.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Orchard J. L., Fekety R., Smith J. R. Antibiotic-associated colitis due to Clostridium difficile in a Kodiak bear. Am J Vet Res. 1983 Aug;44(8):1547–1548. [PubMed] [Google Scholar]
  148. Peach S. L., Borriello S. P., Gaya H., Barclay F. E., Welch A. R. Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis. J Clin Pathol. 1986 Sep;39(9):1013–1018. doi: 10.1136/jcp.39.9.1013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Peikin S. R., Galdibini J., Bartlett J. G. Role of Clostridium difficile in a case of nonantibiotic-associated pseudomembranous colitis. Gastroenterology. 1980 Nov;79(5 Pt 1):948–951. [PubMed] [Google Scholar]
  150. Pepersack F., Labbe M., Nonhoff C., Schoutens E. Use of gas-liquid chromatography as a screening test for toxigenic Clostridium difficile in diarrhoeal stools. J Clin Pathol. 1983 Nov;36(11):1233–1236. doi: 10.1136/jcp.36.11.1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. Peters B. P., Goldstein I. J. The use of fluorescein-conjugated Bandeiraea simplicifolia B4-isolectin as a histochemical reagent for the detection of alpha-D-galactopyranosyl groups. Their occurrence in basement membranes. Exp Cell Res. 1979 May;120(2):321–334. doi: 10.1016/0014-4827(79)90392-6. [DOI] [PubMed] [Google Scholar]
  152. Peterson L. R., Holter J. J., Shanholtzer C. J., Garrett C. R., Gerding D. N. Detection of C. difficile toxin A (enterotoxin) Am J Clin Pathol. 1987 Feb;87(2):298–299. doi: 10.1093/ajcp/87.2.298. [DOI] [PubMed] [Google Scholar]
  153. Peterson L. R., Holter J. J., Shanholtzer C. J., Garrett C. R., Gerding D. N. Detection of Clostridium difficile toxins A (enterotoxin) and B (cytotoxin) in clinical specimens. Evaluation of a latex agglutination test. Am J Clin Pathol. 1986 Aug;86(2):208–211. doi: 10.1093/ajcp/86.2.208. [DOI] [PubMed] [Google Scholar]
  154. Phua T. J., Rogers T. R., Pallett A. P. Prospective study of Clostridium difficile colonization and paracresol detection in the stools of babies on a special care unit. J Hyg (Lond) 1984 Aug;93(1):17–25. doi: 10.1017/s0022172400060885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Pierce P. F., Jr, Wilson R., Silva J., Jr, Garagusi V. F., Rifkin G. D., Fekety R., Nunez-Montiel O., Dowell V. R., Jr, Hughes J. M. Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. J Infect Dis. 1982 Feb;145(2):269–274. doi: 10.1093/infdis/145.2.269. [DOI] [PubMed] [Google Scholar]
  156. Popoff M. R. Bacteriological examination in enterotoxaemia of sheep and lamb. Vet Rec. 1984 Mar 31;114(13):324–324. doi: 10.1136/vr.114.13.324. [DOI] [PubMed] [Google Scholar]
  157. Popoff M. R. Purification and characterization of Clostridium sordellii lethal toxin and cross-reactivity with Clostridium difficile cytotoxin. Infect Immun. 1987 Jan;55(1):35–43. doi: 10.1128/iai.55.1.35-43.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Pothoulakis C., Barone L. M., Ely R., Faris B., Clark M. E., Franzblau C., LaMont J. T. Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem. 1986 Jan 25;261(3):1316–1321. [PubMed] [Google Scholar]
  159. Pothoulakis C., Triadafilopoulos G., Clark M., Franzblau C., LaMont J. T. Clostridium difficile cytotoxin inhibits protein synthesis in fibroblasts and intestinal mucosa. Gastroenterology. 1986 Nov;91(5):1147–1153. doi: 10.1016/s0016-5085(86)80010-5. [DOI] [PubMed] [Google Scholar]
  160. Potvliege C., Labbé M., Yourassowsky E. Gas-liquid chromatography as screening test for Clostridium difficile. Lancet. 1981 Nov 14;2(8255):1105–1105. doi: 10.1016/s0140-6736(81)91296-4. [DOI] [PubMed] [Google Scholar]
  161. Poxton I. R., Aronsson B., Möllby R., Nord C. E., Collee J. G. Immunochemical fingerprinting of Clostridium difficile strains isolated from an outbreak of antibiotic-associated colitis and diarrhoea. J Med Microbiol. 1984 Jun;17(3):317–324. doi: 10.1099/00222615-17-3-317. [DOI] [PubMed] [Google Scholar]
  162. Poxton I. R., Byrne M. D. Demonstration of shared antigens in the genus Clostridium by an enzyme-linked immunosorbent assay. J Med Microbiol. 1984 Apr;17(2):171–176. doi: 10.1099/00222615-17-2-171. [DOI] [PubMed] [Google Scholar]
  163. Poxton I. R., Byrne M. D. Detection of Clostridium difficile toxin by counterimmunoelectrophoresis: a note of caution. J Clin Microbiol. 1981 Sep;14(3):349–349. doi: 10.1128/jcm.14.3.349-349.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Poxton I. R., Byrne M. D. Immunological analysis of the EDTA-soluble antigens of Clostridium difficile and related species. J Gen Microbiol. 1981 Jan;122(1):41–46. doi: 10.1099/00221287-122-1-41. [DOI] [PubMed] [Google Scholar]
  165. Poxton I. R., Cartmill T. D. Immunochemistry of the cell-surface carbohydrate antigens of Clostridium difficile. J Gen Microbiol. 1982 Jun;128(6):1365–1370. doi: 10.1099/00221287-128-6-1365. [DOI] [PubMed] [Google Scholar]
  166. Preston K. M., Griffin J. Complex wound management: a case study. Rehabil Nurs. 1989 Sep-Oct;14(5):269–270. doi: 10.1002/j.2048-7940.1989.tb01117.x. [DOI] [PubMed] [Google Scholar]
  167. Price A. B., Larson H. E., Crow J. Morphology of experimental antibiotic-associated enterocolitis in the hamster: a model for human pseudomembranous colitis and antibiotic-associated diarrhoea. Gut. 1979 Jun;20(6):467–475. doi: 10.1136/gut.20.6.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Prigogine T., Potvliege C., Burette A., Verbeet T., Schmerber J. Pseudomembranous colitis and rifampicin. Chest. 1981 Dec;80(6):766–767. doi: 10.1378/chest.80.6.766. [DOI] [PubMed] [Google Scholar]
  169. Ramirez-Ronda C. H. Letter: Incidence of clindamycin-associated colitis. Ann Intern Med. 1974 Dec;81(6):860–860. doi: 10.7326/0003-4819-81-6-860_1. [DOI] [PubMed] [Google Scholar]
  170. Rautenberg P., Stender F., Ullmann U. Detection of Clostridium difficile Toxin A by immunoblotting. Zentralbl Bakteriol Mikrobiol Hyg A. 1986 Feb;261(1):29–42. doi: 10.1016/s0176-6724(86)80060-8. [DOI] [PubMed] [Google Scholar]
  171. Rehg J. E. Cecal toxin(s) from guinea pigs with clindamycin-associated colitis, neutralized by Clostridium sordellii antitoxin. Infect Immun. 1980 Feb;27(2):387–390. doi: 10.1128/iai.27.2.387-390.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Rehg J. E., Pakes S. P. Implication of Clostridium difficile and Clostridium perfringens iota toxins in experimental lincomycin-associated colitis of rabbits. Lab Anim Sci. 1982 Jun;32(3):253–257. [PubMed] [Google Scholar]
  173. Richards S. M., Hunt B. W. Clostridium sordellii in lambs. Vet Rec. 1982 Jul 3;111(1):22–22. doi: 10.1136/vr.111.1.22-a. [DOI] [PubMed] [Google Scholar]
  174. Rietra P. J., Slaterus K. W., Zanen H. C., Meuwissen S. G. Clostridial toxin in faeces of healthy infants. Lancet. 1978 Aug 5;2(8084):319–319. doi: 10.1016/s0140-6736(78)91723-3. [DOI] [PubMed] [Google Scholar]
  175. Rifkin G. D., Fekety F. R., Silva J., Jr Antibiotic-induced colitis implication of a toxin neutralised by Clostridium sordellii antitoxin. Lancet. 1977 Nov 26;2(8048):1103–1106. doi: 10.1016/s0140-6736(77)90547-5. [DOI] [PubMed] [Google Scholar]
  176. Rifkin G. D., Silva J., Jr, Fekety R. Gastrointestinal and systemic toxicity of fecal extracts from hamsters with clindamycin-induced colitis. Gastroenterology. 1978 Jan;74(1):52–57. [PubMed] [Google Scholar]
  177. Rihn B., Beck G., Monteil H., Lecerf F., Girardot R. Effect of the cytotoxin of Clostridium difficile on cultured hepatoma cells. Biol Cell. 1985;53(1):23–32. doi: 10.1111/j.1768-322x.1985.tb00351.x. [DOI] [PubMed] [Google Scholar]
  178. Rihn B., Scheftel J. M., Girardot R., Monteil H. A new purification procedure for Clostridium difficile enterotoxin. Biochem Biophys Res Commun. 1984 Nov 14;124(3):690–695. doi: 10.1016/0006-291x(84)91013-1. [DOI] [PubMed] [Google Scholar]
  179. Robert A., Bundy G. L., Field S. O., Nezamis J. E., Davis J. P., Hanchar A. J., Lancaster C., Ruwart M. J. Prevention of cecitis in hamsters by certain prostaglandins. Prostaglandins. 1985 Jun;29(6):961–980. doi: 10.1016/0090-6980(85)90221-7. [DOI] [PubMed] [Google Scholar]
  180. Rocca J. M., Pieterse A. S., Rowland R., Hecker R., Rich G. E. Clostridium difficile colitis. Aust N Z J Med. 1984 Oct;14(5):606–610. doi: 10.1111/j.1445-5994.1984.tb05009.x. [DOI] [PubMed] [Google Scholar]
  181. Rolfe R. D., Iaconis J. P. Intestinal colonization of infant hamsters with Clostridium difficile. Infect Immun. 1983 Nov;42(2):480–486. doi: 10.1128/iai.42.2.480-486.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  182. Ruwart M. J., Renis H. E., Erlandson A. L., DeHaan R. M., Nezamis J. E., Lancaster C., Davis J. P. 16,16-dimethyl-prostaglandin E2 inhibits toxin release from Clostridium difficile. Adv Prostaglandin Thromboxane Leukot Res. 1983;12:93–98. [PubMed] [Google Scholar]
  183. Ryan R. W. Considerations in the laboratory diagnosis of antibiotic-associated gastroenteritis. Diagn Microbiol Infect Dis. 1986 Mar;4(3 Suppl):79S–86S. doi: 10.1016/s0732-8893(86)80045-1. [DOI] [PubMed] [Google Scholar]
  184. STERNE M., WENTZEL L. M. A new method for the large-scale production of high-titre botulinum formol-toxoid types C and D. J Immunol. 1950 Aug;65(2):175–183. [PubMed] [Google Scholar]
  185. Saginur R., Fogel R., Begin L., Cohen B., Mendelson J. Splenic abscess due to Clostridium difficile. J Infect Dis. 1983 Jun;147(6):1105–1105. doi: 10.1093/infdis/147.6.1105. [DOI] [PubMed] [Google Scholar]
  186. Sands M., Yungbluth M., Sommers H. M. The non-value of counterimmunoelectrophoresis for the direct rapid detection of Clostridium difficile toxin in stool filtrates. Am J Clin Pathol. 1983 Mar;79(3):375–377. doi: 10.1093/ajcp/79.3.375. [DOI] [PubMed] [Google Scholar]
  187. Schwan A., Sjölin S., Trottestam U., Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis. 1984;16(2):211–215. doi: 10.3109/00365548409087145. [DOI] [PubMed] [Google Scholar]
  188. Sell T. L., Schaberg D. R., Fekety F. R. Bacteriophage and bacteriocin typing scheme for Clostridium difficile. J Clin Microbiol. 1983 Jun;17(6):1148–1152. doi: 10.1128/jcm.17.6.1148-1152.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  189. Sherertz R. J., Sarubbi F. A. The prevalence of Clostridium difficile and toxin in a nursery population: a comparison between patients with necrotizing enterocolitis and an asymptomatic group. J Pediatr. 1982 Mar;100(3):435–439. doi: 10.1016/s0022-3476(82)80455-1. [DOI] [PubMed] [Google Scholar]
  190. Silva J., Fekety R., Werk C., Ebright J., Cudmore M., Batts D., Syrjamaki C., Lukens J. Inciting and etiologic agents of colitis. Rev Infect Dis. 1984 Mar-Apr;6 (Suppl 1):S214–S221. doi: 10.1093/clinids/6.supplement_1.s214. [DOI] [PubMed] [Google Scholar]
  191. Small J. D. Fatal enterocolitis in hamsters given lincomycin hydrochloride. Lab Anim Care. 1968 Aug;18(4):411–420. [PubMed] [Google Scholar]
  192. Smith M. F., Borriello S. P., Clayden G. S., Casewell M. W. Clinical and bacteriological findings in necrotising enterocolitis: a controlled study. J Infect. 1980 Mar;2(1):23–31. doi: 10.1016/s0163-4453(80)91727-2. [DOI] [PubMed] [Google Scholar]
  193. Stark P. L., Lee A., Parsonage B. D. Colonization of the large bowel by Clostridium difficile in healthy infants: quantitative study. Infect Immun. 1982 Mar;35(3):895–899. doi: 10.1128/iai.35.3.895-899.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  194. Stephen J., Redmond S. C., Mitchell T. J., Ketley J., Candy D. C., Burdon D. W., Daniel R. Clostridium difficile enterotoxin (toxin A): new results. Biochem Soc Trans. 1984 Apr;12(2):194–195. doi: 10.1042/bst0120194. [DOI] [PubMed] [Google Scholar]
  195. Sugiyama T., Mukai M., Yamashita R., Sunakawa K. Experimental models of Clostridium difficile enterocolitis in gnotobiotic mice. Prog Clin Biol Res. 1985;181:203–206. [PubMed] [Google Scholar]
  196. Sullivan N. M., Pellett S., Wilkins T. D. Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun. 1982 Mar;35(3):1032–1040. doi: 10.1128/iai.35.3.1032-1040.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  197. Svedhem A., Kaijser B., MacDowall I. Intestinal occurrence of Campylobacter fetus subspecies jejuni and Clostridium difficile in children in Sweden. Eur J Clin Microbiol. 1982 Feb;1(1):29–32. doi: 10.1007/BF02014137. [DOI] [PubMed] [Google Scholar]
  198. Swartzberg J. E., Maresca R. M., Remington J. S. Clinical study of gastrointestinal complications associated with clindamycin therapy. J Infect Dis. 1977 Mar;135 (Suppl):S99–103. doi: 10.1093/infdis/135.supplement.s99. [DOI] [PubMed] [Google Scholar]
  199. Teasley D. G., Gerding D. N., Olson M. M., Peterson L. R., Gebhard R. L., Schwartz M. J., Lee J. T., Jr Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983 Nov 5;2(8358):1043–1046. doi: 10.1016/s0140-6736(83)91036-x. [DOI] [PubMed] [Google Scholar]
  200. Tedesco F. J., Barton R. W., Alpers D. H. Clindamycin-associated colitis. A prospective study. Ann Intern Med. 1974 Oct;81(4):429–433. doi: 10.7326/0003-4819-81-4-429. [DOI] [PubMed] [Google Scholar]
  201. Tedesco F. J. Clindamycin-associated colitis. Review of the clinical spectrum of 47 cases. Am J Dig Dis. 1976 Jan;21(1):26–32. doi: 10.1007/BF01074135. [DOI] [PubMed] [Google Scholar]
  202. Tedesco F. J., Napier J., Gamble W., Chang T. W., Bartlett J. G. Therapy of antibiotic-associated pseudomembranous colitis. J Clin Gastroenterol. 1979 Mar;1(1):51–54. doi: 10.1097/00004836-197903000-00007. [DOI] [PubMed] [Google Scholar]
  203. Thelestam M., Brönnegård M. Interaction of cytopathogenic toxin from Clostridium difficile with cells in tissue culture. Scand J Infect Dis Suppl. 1980;(Suppl 22):16–29. [PubMed] [Google Scholar]
  204. Toffler R. B., Pingoud E. G., Burrell M. I. Acute colitis related to penicillin and penicillin derivatives. Lancet. 1978 Sep 30;2(8092 Pt 1):707–709. doi: 10.1016/s0140-6736(78)92704-6. [DOI] [PubMed] [Google Scholar]
  205. Toothaker R. D., Elmer G. W. Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii. Antimicrob Agents Chemother. 1984 Oct;26(4):552–556. doi: 10.1128/aac.26.4.552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  206. Torres J. F., Cedillo R., Sánchez J., Dillman C., Giono S., Muñoz O. Prevalence of Clostridium difficile and its cytotoxin in infants in Mexico. J Clin Microbiol. 1984 Aug;20(2):274–275. doi: 10.1128/jcm.20.2.274-275.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  207. Trnka Y. M., LaMont J. T. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology. 1981 Apr;80(4):693–696. [PubMed] [Google Scholar]
  208. Vesikari T., Isolauri E., Mäki M., Grönroos P. Clostridium difficile in young children. Association with antibiotic usage. Acta Paediatr Scand. 1984 Jan;73(1):86–91. doi: 10.1111/j.1651-2227.1984.tb09903.x. [DOI] [PubMed] [Google Scholar]
  209. Viscidi R. P., Bartlett J. G. Antibiotic-associated pseudomembranous colitis in children. Pediatrics. 1981 Mar;67(3):381–386. [PubMed] [Google Scholar]
  210. Viscidi R., Willey S., Bartlett J. G. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology. 1981 Jul;81(1):5–9. [PubMed] [Google Scholar]
  211. Wada N., Nishida N., Iwaki S., Ohi H., Miyawaki T., Taniguchi N., Migita S. Neutralizing activity against Clostridium difficile toxin in the supernatants of cultured colostral cells. Infect Immun. 1980 Aug;29(2):545–550. doi: 10.1128/iai.29.2.545-550.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  212. Wald A., Mendelow H., Bartlett J. G. Non-antibiotic-associated pseudomembranous colitis due to toxin-producing Clostridia. Ann Intern Med. 1980 Jun;92(6):798–799. doi: 10.7326/0003-4819-92-6-798. [DOI] [PubMed] [Google Scholar]
  213. Walker R. C., Ruane P. J., Rosenblatt J. E., Lyerly D. M., Gleaves C. A., Smith T. F., Pierce P. F., Jr, Wilkins T. D. Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. Diagn Microbiol Infect Dis. 1986 May;5(1):61–69. doi: 10.1016/0732-8893(86)90092-1. [DOI] [PubMed] [Google Scholar]
  214. Welkon C. J., Long S. S., Thompson C. M., Jr, Gilligan P. H. Clostridium difficile in patients with cystic fibrosis. Am J Dis Child. 1985 Aug;139(8):805–808. doi: 10.1001/archpedi.1985.02140100067032. [DOI] [PubMed] [Google Scholar]
  215. West S. E., Wilkins T. D. Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol. 1982 Feb;15(2):347–349. doi: 10.1128/jcm.15.2.347-349.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  216. Wilson K. H., Kennedy M. J., Fekety F. R. Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol. 1982 Mar;15(3):443–446. doi: 10.1128/jcm.15.3.443-446.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  217. Wilson K. H., Sheagren J. N., Freter R., Weatherbee L., Lyerly D. Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. J Infect Dis. 1986 Mar;153(3):547–551. doi: 10.1093/infdis/153.3.547. [DOI] [PubMed] [Google Scholar]
  218. Wilson K. H., Silva J., Fekety F. R. Suppression of Clostridium difficile by normal hamster cecal flora and prevention of antibiotic-associated cecitis. Infect Immun. 1981 Nov;34(2):626–628. doi: 10.1128/iai.34.2.626-628.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  219. Wu T. C., Fung J. C. Evaluation of the usefulness of counterimmunoelectrophoresis for diagnosis of Clostridium difficile-associated colitis in clinical specimens. J Clin Microbiol. 1983 Apr;17(4):610–613. doi: 10.1128/jcm.17.4.610-613.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  220. Wu T. C., Gersch S. M. Evaluation of a commercial kit for the routine detection of Clostridium difficile cytotoxin by tissue culture. J Clin Microbiol. 1986 Apr;23(4):792–793. doi: 10.1128/jcm.23.4.792-793.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  221. Wu T. C., McCarthy V. P., Gill V. J. Isolation rate and toxigenic potential of Clostridium difficile isolates from patients with cystic fibrosis. J Infect Dis. 1983 Jul;148(1):176–176. doi: 10.1093/infdis/148.1.176. [DOI] [PubMed] [Google Scholar]
  222. Yamakawa K., Nakamura S., Nishida S. Separation of two cytotoxins of Clostridium sordellii strains. Microbiol Immunol. 1985;29(6):553–557. doi: 10.1111/j.1348-0421.1985.tb00857.x. [DOI] [PubMed] [Google Scholar]
  223. Yamakawa K., Nishida S., Nakamura S. C2 toxicity in extract of Clostridium botulinum type C spores. Infect Immun. 1983 Aug;41(2):858–860. doi: 10.1128/iai.41.2.858-860.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  224. Young G. P., Ward P. B., Bayley N., Gordon D., Higgins G., Trapani J. A., McDonald M. I., Labrooy J., Hecker R. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology. 1985 Nov;89(5):1038–1045. doi: 10.1016/0016-5085(85)90206-9. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES